AOD9604, by contrast, is not FDAapproved as an obesity medication, and while safety data are reassuring, its use for weight loss remains offlabel with mixed evidence for effectiveness
Compounded versions may be more accessible, though they are not identical to the brand-name product and quality can vary between compounding pharmacies
Microdosing 5-Amino-1MQ
- This research blend combines 100MG NAD+, 10MG MOTS-c, and 10MG 5-Amino-1MQ in a metabolic pathway-focused format studied in models involving cellular energy metabolism, mitochondrial signaling, NNMT pathway activity, NAD+-related biology, metabolic flexibility, and body-composition pathway research
Every treatment is personalized to your anatomy, your goals, and your timeline